Saudi Aramco’s investment arm, Prosperity7 Ventures, has placed a strategic bet on the medtech industry by funding Cispoly, a Chinese startup specializing in the detection of gynecological cancers.
Prosperity7 Ventures spearheaded the Series B investment round which successfully amassed over 100 million yuan ($14 million). The funding effort also saw contributions from Sunland Fund, a returning investor. These financial endorsements underscore the growing interest in healthcare innovations.
Headquartered in Beijing, Cispoly is at the forefront of women’s health technology. The company’s pioneering efforts have led to the creation of advanced diagnostic tools targeting the early detection of various gynecological cancers, such as those affecting the cervix, ovaries, and endometrium.
With the influx of new funds, Cispoly aims to extend its global reach and intensify its research and development pursuits. The investment will further support the company’s efforts in securing product registrations, a critical step towards international expansion.
Prosperity7’s investment strategy is to nurture startups with the potential to revolutionize technology and business models, contributing to a broader societal benefit. By investing in Cispoly, the venture fund is reinforcing its commitment to advancing global health and technology.